top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.58 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗
 
Via Benzinga
News headline image
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Outlook For Astria Therapeutics ↗
 
Via Benzinga
News headline image
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
News headline image
Dow Dips Over 800 Points; S&P 500 Down 2.8% ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points. 
Via Benzinga
News headline image
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
News headline image
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants ↗
 
Via Benzinga
News headline image
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Investment Conferences
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page